Rafa Laboratories to acquire a significant stake in ExCEEd Orphan and expand its international capabilities in...
JERUSALEM and PRAGUE, Czech Republic, Aug. 1, 2022 /PRNewswire/ --Rafa Laboratories LTD. (Rafa) and ExCEEd Orphan s.r.o (ExCEEd) announced today a strategic collaboration for medicines addressing rare diseases in Central and Eastern Europe (CEE) and Israel. Under the agreement, and as part of its strategy to become an international player, Rafa will invest in ExCEEd an undisclosed amount that shall enable it to strengthen its market access capabilities in the region and move closer to fulfilling its vision to become a leading player in this important mission of pioneering access to patients with rare diseases. Furthermore, the parties shall collaborate on bringing new medicines for rare diseases to both the CEE and Israel.
The worldwide orphan drug market is growing over twice as fast as the non-orphan market, with expected 2021-2026 CAGR of 12%. By 2026, global orphan drug sales are expected to reach $273b and account for 20% of all prescription drug sales1. With a CEE population of approximately 120 million2, a pharmaceutical market value of $24.7b in 20203and growing economies, the demand in CEE for solutions to rare diseases is increasing, while the number of medicines currently available in this region is considerably lower than in the rest of Europe.
A strong vote of confidence in ExCEEd is demonstrated by agreements signed within the last 15 months with leading innovative pharma companies, among them Amryt, Mirum and SERB. These collaborative agreements have laid a sturdy foundation for future alliances in this arena.
Continue read on benzinga.com